本帖最后由 老马 于 2013-3-13 13:43 编辑 / ]+ K% l8 T1 c( O9 M' p+ `
2 \, {' J8 L$ G# ?5 s# Z8 D. ]& `健择（吉西他滨）+顺铂+阿瓦斯汀
) w0 Z! g; T% z; A8 k/ @ Gemzar +Cisplatin + Avastin
. o; y _7 [1 Whttp://annonc.oxfordjournals.org/content/21/9/1804.full& B2 T1 {! b% S0 z0 {6 M# l5 d0 ?5 \
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) + T- j- K: U2 a+ E5 H( Z& B) T0 q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. . U/ i1 r4 o# f( a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 G9 p- |0 V# ]; ^- ^
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 495)
- V& A' Y% k m P+ j. s/ S5 G9 _, j: T
华为网盘附件：+ e4 D" s* r8 _/ `
【华为网盘】ava.JPG
5 u+ L* d9 y( M |
显身卡
